Acurx Pharmaceuticals, Inc.

  • Home
  • About
    • Management / Consultants
    • Scientific / Corporate Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • Ibezapolstat
    • ACX-375C
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Videos
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Presentations

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Balance Sheet
    • Income Statement
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • Company Information

  • Overview
  • Presentations
  • Management Team
  • Contacts
  • FAQ
Poster Presentation and Abstract from ID Week (October 2021) titled “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.” presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy”

Poster Presentation and Abstract from ID Week (October 2021) titled “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.” presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy”

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile

Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile

In Vitro Activity of the Novel Antibacterial ACX-362E against Clostridioides difficile

In Vitro Activity of the Novel Antibacterial ACX-362E against Clostridioides difficile

RSS
© 2022 Acurx Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap